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Background: Dihydroergotamine (DHE) is an acute antimigraine agent that displays affinity for dopamine D2-like
receptors, serotonin 5-HT1/2 receptors and α1/α2-adrenoceptors. Since activation of vascular α1/α2-adrenoceptors
results in systemic vasopressor responses, the purpose of this study was to investigate the specific role of α1- and
α2-adrenoceptors mediating DHE-induced vasopressor responses using several antagonists for these receptors.
Methods: For this purpose, 135 male Wistar rats were pithed and divided into 35 control and 100 pretreated
i.v. with ritanserin (100 μg/kg; to exclude the 5-HT2 receptor-mediated systemic vasoconstriction). Then, the
vasopressor responses to i.v. DHE (1–3100 μg/kg, given cumulatively) were determined after i.v. administration
of some α1/α2-adrenoceptor antagonists.
Results: In control animals (without ritanserin pretreatment), the vasopressor responses to DHE were: (i) unaffected
after prazosin (α1; 30 μg/kg); (ii) slightly, but significantly, blocked after rauwolscine (α2; 300 μg/kg); and (iii) markedly
blocked after prazosin (30 μg/kg) plus rauwolscine (300 μg/kg). In contrast, after pretreatment with ritanserin, the
vasopressor responses to DHE were: (i) attenuated after prazosin (α1; 10 and 30 μg/kg) or rauwolscine (α2; 100 and
300 μg/kg); (ii) markedly blocked after prazosin (30 μg/kg) plus rauwolscine (300 μg/kg); (iii) attenuated after
5-methylurapidil (α1A; 30–100 μg/kg), L-765,314 (α1B; 100 μg/kg), BMY 7378 (α1D; 30–100 μg/kg), BRL44408 (α2A;
100–300 μg/kg), imiloxan (α2B; 1000–3000 μg/kg) or JP-1302 (α2C; 1000 μg/kg); and (iv) unaffected after the
corresponding vehicles (1 ml/kg).
Conclusion: These results suggest that the DHE-induced vasopressor responses in ritanserin-pretreated pithed rats are
mediated by α1- (probably α1A, α1B and α1D) and α2- (probably α2A, α2B and α2C) adrenoceptors. These findings could
shed light on the pharmacological profile of the vascular side effects (i.e. systemic vasoconstriction) produced by DHE
and may lead to the development of more selective antimigraine drugs devoid vascular side effects.
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Both ergotamine and dihydroergotamine (DHE) share
structural similarities with serotonin, dopamine and
(nor)adrenaline, and have been shown: (i) to display affinity
for a wide variety of receptors including serotonin 5-HT1/2,
dopamine D2-like and α1/α2-adrenoceptors [1]; and (ii) to
be effective in the acute treatment of migraine [2]. Never-
theless, unlike ergotamine, DHE (a hydrogenated ergot syn-
thesized by reducing an unsaturated bond in ergotamine)
displays a much lower vasoconstrictor and emetic potential
[1]. Indeed, recent pharmaceutical developments have
introduced the use of inhalable DHE (iDHE) in nasal sprays
and oral inhalers; these novel iDHE medications are better
tolerated than i.v. DHE and provide an important option
for the acute therapy of migraine [3–5].
Regarding the systemic vasoconstrictor potential of DHE,
Roquebert and Grenié [6] have reported that DHE
produces vasopressor responses in pithed rats by activation
of α2 (but not α1) adrenoceptors, since such responses
were: (i) attenuated by 500 and 1000 μg/kg yohimbine (an
α2-adrenoceptor antagonist); and (ii) apparently resistant to
blockade by 500 μg/kg prazosin (an α1-adrenoceptor
antagonist). At that time, however, it was unknown that:
(i) DHE also displays a high affinity for 5-HT2A receptors
(pKi = 8.54) [7], whose activation in resistance blood
vessels induces vasopressor responses [8] that may have
masked the capability of DHE to activate α1-adrenoceptors;
and (ii) yohimbine displays a moderate affinity for
α1-adrenoceptors (pKi = 6.6) [9].
Since, in addition, DHE can interact with all α1/α2-adre-
noceptor subtypes (see Table 1), all of the above findings
taken together raise the question whether systemic 5-
HT2A receptor blockade would unmask the role of α1-Table 1 Binding affinity constants (pKi) of the drugs used in this
study for α1- and α2-adrenoceptors
Drug α1 α2
Ritanserin 6.71,b 6.21,b
Drugs α1A α1B α1D α2A α2B α2C
5-Methylurapidil 9.02,b 7.42,b 7.62,b 6.23 6.43 6.93
L-765,314 6.34,b 8.34,b 7.34,b N.D. N.D. N.D.
BMY 7378 7.12,b 7.52,b 9.02,b 5.15,b 5.15,b 5.15,b
BRL44408 N.D. N.D. N.D. 8.76,b 6.96,b 6.87
Imiloxan < 48 < 48 < 48 5.58 7.38,b 6.09
JP-1302 N.D. N.D. N.D. 5.510 5.810 7.610
Prazosin 9.511,b 9.711,b 9.611,b 5.612 6.912 7.212
Rauwolscine 5.313 5.913 6.413 8.412 8.312 9.112
Dihydroergotamine 8.614,b,a 8.014,b,a 7.814,b,a 8.715 8.015 9.015
Data taken from the following references: 1 [37]; 2 [38]; 3 [39]; 4 [40]; 5 [41]; 6
[42]; 7 [43]; 8 [44]; 9 [45]; 10 [46]; 11 [47]; 12 [48]; 13 [49]; 14 [50]; and 15 [7]
All values have been presented as pKi, except for:
a pA2
b Values for rodent receptors
N.D. stands for “not determined”adrenoceptors and, consequently, the capability of
prazosin to block the vasopressor responses to DHE.
Interestingly, ergotamine produces vasopressor responses
in pithed rats via the activation of α1A, α1B, α1D, α2A and
α2C (but not α2B)-adrenoceptor subtypes [10], but no
study has yet reported the specific role of these subtypes
in DHE-induced vasopressor responses in pithed rats.
This is an experimental model predictive of systemic
(cardio)vascular side effects [11, 12]; since this model is
devoid of a functional central nervous system (see General
methods below), one can categorically exclude the com-
pensatory baroreflex mechanisms typically observed in
intact or anaesthetized animals.
Based on the above findings and using antagonists
with relative selectivity for α1- and α2-adrenoceptors
(Table 1) at blocking doses (see below) in pithed rats
[10, 13], the present study has re-investigated the vaso-
pressor responses to DHE in an attempt to: (i) analyze
the specific role of α1- and α2-adrenoceptors in control
animals; and (ii) ascertain the possible involvement of
their corresponding subtypes in animals pretreated with
ritanserin (100 μg/kg, i.v.). Ritanserin is an antagonist
with a very high affinity for 5-HT2A receptors (pKi = 9.5)
[14] and very low affinity for α1- and α2-adrenoceptors
(see Table 1) that, in pithed rats: (i) is devoid of α1-adre-
noceptor blocking properties (up to 3000 μg/kg, i.v.) on
the vasopressor responses to phenylephrine [15]; and (ii)
practically abolishes (at 30 μg/kg, i.v.) the cardiovascular
responses mediated by 5-HT2A receptors [16].
Methods
Animals
Experiments were carried out in 135 male normotensive
Wistar rats (250–300 g, 8 weeks of age). The animals were
housed in a special room at a constant temperature (22 ±
2 °C) and humidity (50%), and maintained at a 12/12-h
light/dark cycle (light beginning at 7:00 am), with ad libi-
tum access to food and water. The animal procedures, the
experimental protocols and number of animals used in
this investigation were reviewed and approved by our
Institutional Ethics Committee on the use of animals in
scientific experiments (CICUAL Cinvestav; protocol num-
ber 507–12) and followed the regulations established by
the Mexican Official Norm (NOM-062-ZOO-1999), in
accordance with the ARRIVE (Animal Research: Report-
ing In Vivo Experiments) reporting guidelines for the care
and use of laboratory animals.
General methods
After anaesthesia with sodium pentobarbital (60 mg/kg, i.p.)
and cannulation of the trachea, the 135 rats were pithed by
inserting a stainless steel rod through the orbit and foramen
magnum, and down the vertebral foramen [17]. Then, the
animals were artificially ventilated with room air using a
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volume: 20 ml/kg) as previously established [18]. After
cervical bilateral vagotomy, catheters were placed in: (i) the
left and right femoral veins for i.v. bolus injections of DHE
or antagonists, respectively; and (ii) the left carotid artery,
connected to a Grass pressure transducer (P23XL), for
recording arterial blood pressure. Heart rate was measured
with a tachograph (7P4, Grass Instrument Co., Quincy, MA,
USA), triggered from the blood pressure signal. Both param-
eters were recorded by a model 7 Grass polygraph (Grass
Instrument Co., Quincy, MA, USA).
Then, the 135 animals were divided into six main sets,
namely, set 1 (n = 10), set 2 (n = 20), set 3 (n = 15), set 4
(n = 25), set 5 (n = 30) and set 6 (n = 35), as shown in Fig.
1. After the haemodynamic conditions were stable for at
least 30 min, baseline values of diastolic blood pressure (a
more accurate indicator of peripheral vascular resistance)Fig. 1 Number of pithed rats utilized in the six main sets and their subseque
in the present study. The animals in set 1, set 2, and the first box of set 3 repr
On the other hand, the second and third boxes of set 3, as well as se
100 μg/kg ritanserin (n = 100)and heart rate were determined. At this point, the effects
produced by i.v. bolus injections of DHE (1, 3.1, 10, 31,
100, 310, 1000 and 3100 μg/kg; given cumulatively) on
diastolic blood pressure and heart rate were investigated
in animals with different pretreatments (see Fig. 1 and
below for further details). In all cases, before eliciting the
dose-response curves to DHE, a period of 10 min was
allowed to elapse after the i.v. administration of antago-
nists or of their corresponding vehicles (given in a volume
of 1 ml/kg); this period is appropriate for allowing drugs
to interact with their corresponding receptors, as previ-
ously reported [10, 13].
Moreover, the cumulative dose-response curves to
DHE were completed in about 50 min, and the intervals
between the different doses of DHE (given in volumes of
1 ml/kg each) ranged between 4 and 7 min (as in each
case we waited until the vasopressor response to thent division into the different groups (n = 5 each with no exception) used
esent the control group animals (without ritanserin-pretreatment, n = 35).
ts 4, 5 and 6 represent the animals that were pretreated i.v. with
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dose schedule was also applied for the vehicle of DHE
(see below). The body temperature of each pithed rat
(monitored with a rectal thermometer) was maintained
at 37°C by a lamp.Experimental protocols
For the purpose of analysing the pharmacological profile
of the receptors involved in the vasopressor responses to
DHE, the six main sets of rats (as described above) were
subsequently divided into different pretreatment groups
(n = 5 each with no exception; see Fig. 1), for performing
the following protocols.Protocol I. Effect of DHE on diastolic blood pressure
The first set of rats (n = 10; control animals with no pre-
treatment) was divided into two groups (n = 5 each) that
received, as previously pointed out, i.v. bolus injections
of: (i) 20% propylene glycol (vehicle of DHE, 1 ml/kg;
given 8 consecutive times); and (ii) DHE (1, 3.1, 10, 31,
100, 310, 1000 and 3100 μg/kg). The effects produced by
each dose of these compounds on diastolic blood pres-
sure and heart rate were evaluated.Protocol II. Effect of α-adrenoceptor antagonists on
DHE-induced vasopressor responses in control animals
(non-pretreated with ritanserin)
The second set (n = 20, non-pretreated animals) was
divided into four groups (n = 5 each) that received i.v. bolus
injections of: (i) saline (vehicle of prazosin and rauwolscine,
1 ml/kg); (ii) 30 μg/kg prazosin; (iii) 300 μg/kg rauwolscine;
and (iv) the combination of 30 μg/kg prazosin plus 300 μg/
kg rauwolscine. After 10 min, a dose-response curve to
DHE was elicited as previously described.Protocol III. Effect of ritanserin pretreatment on the
DHE-induced vasopressor responses
The third set (n = 15), divided into 3 groups (n = 5 each),
received i.v. bolus injections of: (i) 1% ascorbic acid
(vehicle of ritanserin; 1 ml/kg); (ii) 100 μg/kg ritanserin;
and (iii) 100 μg/kg ritanserin followed by 1 ml/kg
physiological saline (vehicle of the α1- and α2-adreno-
ceptor antagonists). After 10 min, a dose-response curve
to DHE was elicited as previously described. Considering
the pretreatment of the last group (i.e. 100 μg/kg ritan-
serin plus 1 ml/kg physiological saline), the fourth, fifth
and sixth sets were systematically pretreated with ritan-
serin (100 μg/kg, i.v.) and then with blocking doses of
several α1- and α2-adrenoceptor antagonists (see Fig. 1)
as follows.Protocol IV. Effect of α-adrenoceptor antagonists on
DHE-induced vasopressor responses in ritanserin-
pretreated animals
The fourth set (n = 25; pretreated with ritanserin), divided
into five groups (n = 5 each), received i.v. injections of: (i)
prazosin (10 μg/kg); (ii) prazosin (30 μg/kg); (iii) rauwolscine
(100 μg/kg); (iv) rauwolscine (300 μg/kg); and (v) the com-
bination prazosin (30 μg/kg) plus rauwolscine (300 μg/kg).
Ten min later, a dose-response curve to DHE was elicited as
described above.
Protocol V. Effect of α1-adrenoceptor antagonists on
DHE-induced vasopressor responses in ritanserin-
pretreated animals
The fifth set (n = 30; pretreated with ritanserin), divided
into six groups (n = 5 each), received i.v. injections of: (i)
5-methylurapidil (30 μg/kg); (ii) 5-methylurapidil
(100 μg/kg); (iii) L-765,314 (30 μg/kg); (iv) L-765,314
(100 μg/kg); (v) BMY 7378 (30 μg/kg); and (vi) BMY
7378 (100 μg/kg). Ten min thereafter, a dose-response
curve to DHE was elicited.
Protocol VI. Effect of α2-adrenoceptor antagonists on
DHE-induced vasopressor responses in ritanserin-
pretreated animals
The sixth set (n = 35; pretreated with ritanserin), divided
into seven groups (n = 5 each), received i.v. injections of:
(i) BRL44408 (100 μg/kg); (ii) BRL44408 (300 μg/kg);
(iii) imiloxan (300 μg/kg); (iv) imiloxan (1000 μg/kg); (v)
imiloxan (3000 μg/kg); (vi) JP-1302 (300 μg/kg); and (vii)
JP-1302 (1000 μg/kg). After 10 min, a dose-response
curve to DHE was elicited.
Data presentation and statistical evaluation
All data in the text and figures are presented as the means
± S.E.M. It is noteworthy that the data and statistical
analysis used in the present study comply with the recom-
mendations on experimental design and analysis in
pharmacology, including that the data subjected to statis-
tical analysis should have a minimum of n = 5 independent
samples/individuals per group [19]. The changes on the
baseline values of diastolic blood pressure and heart rate
produced by i.v. bolus injections of DHE were determined
after the administration of vehicles or antagonists. The
difference between the changes in diastolic blood pressure
within one subgroup of animals was evaluated with
Student-Newman-Keul’s test, once a two-way repeated
measures analysis of variance revealed that the samples
represented different populations [20]. Statistical signifi-
cance was accepted at P < 0.05.
Drugs
Apart from the anaesthetic (sodium pentobarbital), the
compounds used in the present study (obtained from the
Table 2 Values of DBP and HR before and 10 min after
administration of compounds
Treatment Doses
(μg/kg)
Diastolic blood
pressure (DBP)
(mm Hg)
Heart rate (HR)
(beats/min)
Before After Before After
20% (v/v) propylen
glycol
1a 55 ± 11 55 ± 12 200 ± 1 200 ± 1
Dihydroergotamine 3100 b b 253 ± 45 285 ± 38
Salinec 1a 44 ± 5 44 ± 5 232 ± 11 232 ± 11
Prazosinc 30 42 ± 3 42 ± 3 234 ± 8 232 ± 9
Rauwolscinec 300 48 ± 3 51 ± 3 235 ± 11 244 ± 8
Prazosin+rauwolscinec 30 + 300 38 ± 3 41 ± 5 252 ± 10 234 ± 8
1% (w/v) ascorbic acid 1a 57 ± 3 60 ± 3 220 ± 12 220 ± 12
Ritanserin 100 70 ± 8 70 ± 8 193 ± 13 193 ± 13
Saline 1a 68 ± 10 65 ± 9 201 ± 26 203 ± 27
Prazosin 10
30
74 ± 11
61 ± 5
75 ± 10
61 ± 6
243 ± 8
183 ± 31
245 ± 17
183 ± 31
Rauwolscine 100
300
63 ± 5
51 ± 3
60 ± 5
47 ± 4
213 ± 7
238 ± 13
214 ± 8
240 ± 14
Prazosin + rauwolscine 30 + 300 51 ± 4 45 ± 5 218 ± 9 224 ± 14
5-methylurapidil 30
100
50 ± 7
54 ± 9
51 ± 6
52 ± 8
228 ± 15
232 ± 14
224 ± 12
236 ± 16
L-765,314 30 68 ± 8 65 ± 8 238 ± 20 240 ± 16
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ide; rauwolscine hydrochloride; 5-methylurapidil; imiloxan
hydrochloride; (2S)-4-(4-amino-6,7-dimethoxy-2-quinazo-
linyl)-2-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazine
carboxylic acid, phenylmethyl ester hydrate (L-765,314
hydrate); 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-
8-azaspiro[4.5]decane-7,9-dione dihydrochloride (BMY
7378 dihydrochloride); propylene glycol (PPG); and L-
ascorbic acid (Sigma Chemical Co., St. Louis, MO,
U.S.A.); 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5
-dihydroimidazole maleate (BRL44408 maleate) (Tocris
Cookson Inc., Ellisville, MO, USA); acridin-9-yl-[4-(4-
methylpiperazin-1-yl)-phenyl amine] hydrochloride (JP-
1302 hydrochloride) (gift: Orion Corporation ORION
PHARMA, Turku, Finland); and dihydroergotamine mes-
ylate (gift: Novartis Pharma, Mexico City, Mexico). All
compounds were dissolved in physiological saline. When
needed, 1% ascorbic acid was used to dissolve ritanserin
or 20% PPG (dissolved in bidistilled water) to dissolve
DHE. Initially, DHE (3100 μg/ml) was dissolved in 20%
PPG and the subsequent solutions were finally diluted
with physiological saline. Fresh solutions were prepared
for each experiment.100 64 ± 8 63 ± 10 226 ± 11 226 ± 11
BMY 7378 30
100
68 ± 9
63 ± 3
66 ± 10
60 ± 3
240 ± 12
256 ± 12
238 ± 12
251 ± 13
BRL44408 100
300
65 ± 4
52 ± 8
65 ± 4
53 ± 9
232 ± 22
228 ± 13
228 ± 20
225 ± 15
Imiloxan 300
1000
3000
70 ± 10
69 ± 10
68 ± 6
69 ± 9
66 ± 11
66 ± 7
246 ± 9
247 ± 9
268 ± 16
248 ± 9
252 ± 7
271 ± 16
JP-1302 300
1000
58 ± 3
63 ± 7
58 ± 3
62 ± 10
247 ± 14
212 ± 10
278 ± 13
212 ± 10
Values are presented as means ± SEM
a1 ml/kg
bThese values were determined before and after 1, 3.1, 10, 31, 100, 310, 1000
and 3100 μg/kg DHE, and are shown in Figs. 2, 3, 4, 5, and 6
cThese values were obtained from control rats (non-treated with ritanserin)Results
Systemic haemodynamic variables
The baseline values of diastolic blood pressure and heart
rate in the 135 pithed rats were 59 ± 2 mmHg and 230 ± 4
beats/min, respectively. These variables remained practic-
ally unchanged (P > 0.05; as compared with the correspond-
ing untreated control group) in the groups of animals
pretreated with all doses of the antagonists or their vehicles
(see Table 2), as previously reported [10, 21]. In contrast,
i.v. bolus injections of DHE (1, 3.1, 10, 31, 100, 310, 1000
and 3100 μg/kg; given cumulatively), but not of the corre-
sponding volumes of vehicle (20% PPG, 1 ml/kg; given 8
times), produced dose-dependent vasopressor responses in
untreated control animals (Fig. 2a).Effects of vehicle or α-adrenoceptor antagonists on
the vasopressor responses to DHE in animals without
ritanserin-pretreatment
Figure 2 (b, c, d and e) shows that the vasopressor re-
sponses to DHE in pithed rats without ritanserin-
pretreatment, which remained unchanged (P > 0.05) after
i.v. administration of 1 ml/kg saline (vehicle of the α1- and
α2-adrenoceptor antagonists; Fig. 2b) were: (i) resistant to
blockade (P > 0.05) after 30 μg/kg prazosin (α1; Fig. 2c);
(ii) slightly (though significantly) attenuated after 300 μg/
kg rauwolscine (at 100, 310, 1000 and 3100 μg/kg DHE)
(α2; Fig. 2d); and (iii) markedly blocked (P < 0.05) after the
combination 30 μg/kg prazosin plus 300 μg/kg rauwols-
cine (at 31, 100, 310, 1000 and 3100 DHE) (Fig. 2e).Effects of vehicles or ritanserin on the vasopressor
responses to DHE
Figure 3 illustrates that the vasopressor responses to DHE in
the control (untreated) animals: (i) did not significantly differ
from those elicited in the animals pretreated with 1% ascor-
bic acid (vehicle of ritanserin; 1 ml/kg, i.v.); and (ii) were sig-
nificantly blocked at 310, 1000 and 3100 μg/kg DHE
(whereas those produced by lower doses of DHE remained
unaffected) in the animals pretreated with 100 μg/kg ritan-
serin or with 100 μg/kg ritanserin followed by 1 ml/kg saline
(vehicle of the α1- and α2-adrenoceptor antagonists).
Effects of vehicle or the α-adrenoceptor antagonists
on the vasopressor responses to DHE in ritanserin-
pretreated rats
Figures 4, 5 and 6 show that in ritanserin-pretreated
animals, the vasopressor responses to DHE (as com-
pared with vehicle-treated animals; control), were:
Fig. 2 a Vasopressor responses produced by i.v. bolus injections of either dihydroergotamine (○; 1, 3.1, 10, 31, 100, 310, 1000 and 3100 μg/kg,
given cumulatively) or equivalent volumes of 20% propylene glycol (☐; PPG, 1 ml/kg given 8 times consecutively). b-e Increases in diastolic blood
pressure produced by i.v. dihydroergotamine (1–3100 μg/kg) after i.v. treatment with: (b) saline (☐, 1 ml/kg); (c) 30 μg/kg prazosin (△); (d) 300 μg/kg
rauwolscine (▽); or (e) the combination of 30 μg/kg prazosin plus 300 μg/kg rauwolscine (◇) (n = 5 each). Solid symbols (●,▼,◆) represent
significantly different responses (P < 0.05) versus the corresponding volume of 20% PPG (☐), or versus the saline group (control, ☐) δ P < 0.05 versus
30 μg/kg prazosin (e). λ P < 0.05 versus 300 μg/kg rauwolscine (e). Note that the responses to DHE in the group pretreated with 1 ml/kg saline (b) is
the same as that depicted in (c), (d) and (e), but they are illustrated here for comparative purposes. Moreover, for the sake of clarity when making
comparisons, the responses produced after prazosin or rauwolscine in (e) are the same as those shown in (c) and (d). Data are shown as means ± SEM.
Δ Diastolic blood pressure stands for “increases in diastolic blood pressure”
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treated with the antagonists prazosin (α1, 10 and 30 μg/kg;
Fig. 4a) or rauwolscine (α2, 100 and 300 μg/kg; Fig. 4b), with
this blockade being dose-dependent and apparently more
marked with rauwolscine. These results clearly contrast
with those shown in Fig. 2d (see above). After treatment
with the combination 30 μg/kg prazosin plus 300 μg/kg
rauwolscine, the blockade of the response to 3100 μg/kg
DHE was even more pronounced (P < 0.05) than that pro-
duced by each antagonist given individually (Fig. 4c).
Figure 5) Dose-dependently blocked in animals treated
with 30–100 μg/kg of 5-methylurapdil (α1A; Fig. 5a) or
BMY 7378 (α1D; Fig. 5c), and blocked only by 100 μg/kg
of L-765,314 (α1B; Fig. 5b).
Figure 6) (i) Dose-dependently blocked in animals treated
with 100–300 μg/kg BRL44408 (α2A; Fig. 6a); (ii) signifi-
cantly attenuated, but not dose-dependently blocked, by
1000–3000 μg/kg imiloxan (α2B; Fig. 6b); and (iii) blocked
only by 1000 μg/kg JP-1302 (α2C; Fig. 6c).
It is worthy of note that in Figs. 4, 5 and 6 the dose-
response curve to DHE elicited in the group pretreated
with 100 μg/kg ritanserin followed by 1 ml/kg saline
(control) is the same as that shown in Fig. 3 but, for the
sake of clarity, it was considered as a control for com-
parative purposes.Discussion
General
In addition to the implications discussed below, our find-
ings show that i.v. pretreatment with 100 μg/kg ritanserin
(a dose devoid of α1-adrenoceptor blockade in pithed rats
[15]) is a conditio sine qua non for demonstrating the
blockade produced by prazosin alone (and the role of α1-
adrenoceptors) in the DHE vasopressor responses. In keep-
ing with this view: (i) in animals without ritanserin-
pretreatment the vasopressor responses to DHE remained
unchanged after 30 μg/kg prazosin (Fig. 2c), a dose that
very potently blocks the α1-adrenoceptors mediating vaso-
pressor responses in pithed rats [15]; and (ii) a component
of these vasopressor responses (particularly at 310, 1000
and 3100 μg/kg DHE) is mediated by 5-HT2 receptors in
view of the blockade produced by 100 μg/kg ritanserin
(Fig. 3), whereas the ritanserin-resistant component is
mediated by other receptors. In this respect, our findings
showing that the remaining vasopressor responses to
DHE after ritanserin-pretreatment were attenuated by 10
and 30 μg/kg prazosin (Fig. 4a) and that they were mark-
edly blocked by 100 and 300 μg/kg rauwolscine (Fig. 4b)
establish the involvement of rauwolscine-sensitive α2-
adrenoceptors and, to a lesser extent, of prazosin-sensitive
α1-adrenoceptors. In agreement with our findings,
Fig. 3 Increases in diastolic blood pressure produced by i.v.
dyhydroergotamine (1–3100 μg/kg) after i.v. treatment with 1%
ascorbic acid (△, 1 ml/kg); 100 μg/kg ritanserin (☐); or 100 μg/kg
ritanserin followed by 1 ml/kg saline (◇) (n = 5 each). Empty
symbols depict either control responses in untreated animals (○)
or non-significant (P> 0.05) responses (△, ☐,◇) versus the control
group (○). Solid symbols (■,◆) represent significantly different re-
sponses (P < 0.05) versus the control group (○) or versus the group
pretreated with 1% ascorbic acid (△). Data are shown as means ±
SEM. Δ Diastolic blood pressure stands for “increases in diastolic
blood pressure”
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prazosin (i.v.) failed to block the vasopressor re-
sponses to DHE in pithed rats without pretreatment
with a 5-HT2 receptor antagonist. Accordingly, this
apparent failure by 30 μg/kg prazosin (Fig. 2c) or
500 μg/kg prazosin [6] implies that activation of
vascular 5-HT2 receptors by higher doses of DHE,
which displays a high affinity for 5-HT2A receptors
(pKi = 8.54) [7], may have masked the blockade of α1-adre-
noceptors by prazosin. Certainly, prazosin has higher affin-
ity (approximately 1 to 2 logarithmic units) than DHE for
α1-adrenoceptors (Table 1). However, the affinity (pKi) ofprazosin for 5-HT2 receptors (if any) is <<4 [22], whereas
that of DHE is 8.54 (see above). Therefore, it is highly
unlikely that prazosin is blocking 5-HT2 receptors. This
suggestion is reinforced when considering that the blockade
produced by the combination 30 μg/kg prazosin plus
300 μg/kg rauwolscine in the absence of ritanserin was
more pronounced than that produced by rauwolscine alone
(Fig. 2e). This line of reasoning can also account for the
higher potency of blockade by rauwolscine in ritanserin-
pretreated rats (Fig. 4b) as compared to that in animals
without ritanserin pretreatment (Fig. 2d). These findings,
taken together, may suggest that DHE-induced vasopressor
responses involve the sum of a combination of effects
mediated by activation of 5-HT2A receptors, α1-adrenocep-
tors and α2-adrenoceptors.
In addition, our experimental approach with ritanserin
pretreatment further suggests that the vasopressor
responses to DHE could be mainly mediated by α1-
(probably α1A, α1B and α1D) and α2- (probably α2A, α2B
and α2C) adrenoceptors, although some caution should
be exerted when interpreting the “subtype selectivity” of
the compounds used (see below and Table 1), as these
responses were blocked by the antagonists: (i) 5-
methylurapidil (α1A), L-765,314 (α1B) or BMY 7378
(α1D) (Fig. 5); and (ii) BRL44408 (α2A), imiloxan (α2B)
or JP-1302 (α2C) (Fig. 6).Systemic haemodynamic variables
Our results in pithed rats show that DHE (adminis-
tered cumulatively) produced dose-dependent in-
creases in diastolic blood pressure (Fig. 2a) without
significantly affecting heart rate (Table 2), as previ-
ously reported [6, 10, 21]. In this respect, since the
central nervous system is not operative in pithed rats
(see General methods section), the influence of central
baroreflex mechanisms can be categorically excluded.
Moreover, DHE was administered cumulatively be-
cause it produced sustained and long-lasting vasopres-
sor responses, which may be due to the slow
dissociation of the drug-receptor complex [23, 24];
however, our study provides no evidence whatsoever
to support this view. Additionally, the baseline values
of diastolic blood pressure and heart rate remaining
practically unchanged by the α-adrenoceptor antago-
nists (Table 2) imply that their effects on the
responses to DHE are: (i) unrelated to cardiovascular
changes or physiological antagonism; and (ii) medi-
ated by the direct interaction with its corresponding
receptor. On the other hand, the difference in the
baseline values of diastolic blood pressure in the
different groups of animals (Table 2) may be attrib-
uted to biological variability, as observed in previous
studies [10, 11, 15].
Fig. 4 Increases in diastolic blood pressure produced by i.v. dihydroergotamine (1–3100 μg/kg) after i.v. treatment with: (a) prazosin; (b) rauwolscine;
or (c) the combination of prazosin plus rauwolscine in animals pretreated (i.v.) with 100 μg/kg ritanserin. Empty symbols depict either: (i) the responses
to DHE in the group pretreated with 100 μg/kg ritanserin followed by 1 ml/kg saline (◇, which represent the same data as those shown in Fig. 3, but
it is illustrated here as the control for comparative purposes); or (ii) non-significant responses (△, ▽) versus control (◇). Solid symbols (▲,▼, ) represent
significantly different responses (P < 0.05) versus control (◇). δ P< 0.05 versus 10 μg/kg prazosin (a), 100 μg/kg rauwolscine (b) or 30 μg/kg prazosin (c).
λ P< 0.05 versus 300 μg/kg rauwolscine (c). Note that the responses to DHE in the groups pretreated with either 30 μg/kg prazosin (a) or
300 μg/kg rauwolscine (b) are the same as those depicted in (c), but they are illustrated here for comparative purposes. Data are shown
as means ± SEM. Δ Diastolic blood pressure stands for “increases in diastolic blood pressure”
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vasopressor responses to DHE
DHE displays affinity for a wide variety of receptors [1], with
the same nanomolar affinity for rat α1-adrenoceptors (pKi:
8.0) and rat α2-adrenoceptors (pKi: 8.0) [7]. Interestingly,
DHE can also interact with all α1- and α2-adrenoceptor sub-
types (see Table 1). These findings may help explain, within
the context of our study, the complex interactions of DHE.
Within the bounds of adrenergic mechanisms in our study
using ritanserin-pretreated rats, the functional role of α1-
and α2-adrenoceptors in the vasopressor responses to DHE
is clearly established, as these responses were: (i) blocked by
prazosin (10–30 μg/kg; Fig. 4a) or by rauwolscine (100–
300 μg/kg; Fig. 4b); and (ii) further blocked (particularly the
response to 3100 μg/kg DHE) by the combination of prazo-
sin plus rauwolscine (Fig. 4c). Certainly, in pithed rats,
30 μg/kg prazosin and 300 μg/kg rauwolscine are doses high
enough to completely block the vasopressor responses
mediated by, respectively, α1-adrenoceptors [15] and α2-
adrenoceptors [13]. Nonetheless, there were some import-
ant differences in the profile of blockade produced by these
antagonists. Indeed, the partial blockade of the DHEresponses by 30 μg/kg prazosin, being slightly more pro-
nounced than that produced by 10 μg/kg prazosin (Fig. 4a)
may suggest that it was already a supramaximal dose that,
in addition to completely blocking α1-adrenoceptors, could
have weakly blocked α2-adrenoceptors (particularly the α2B
and α2C-adrenoceptor subtypes, for which it displays a mod-
erate affinity; Table 1). In contrast, the marked blockade by
300 μg/kg rauwolscine, being more pronounced than that
by 100 μg/kg rauwolscine (Fig. 4b), may suggest (although
does not directly prove) a major role of α2-adrenoceptors
(as compared to α1-adrenoceptors). This suggestion may
help partly explain why Roquebert and Grenié [6] could
show the role of α2-adrenoceptors, but not of α1-adrenocep-
tors, in the DHE responses in Wistar rats without 5-HT2 re-
ceptor blockade. Admittedly, Roquebert and Grenié [6]: (i)
did not analyse the effects of the combination prazosin + yo-
himbine as we did with the combination prazosin plus rau-
wolscine in animals without ritanserin pretreatment (Fig.
2e); and (ii) used older rats (300–350 g) anaesthetised with
ether. Certainly, the functional expression of rat vascular
α1-adrenoceptor subtypes depends on several factors,
including age [25].
Fig. 5 Increases in diastolic blood pressure by i.v. dihydroergotamine (1–3100 μg/kg) after i.v. treatment with: (a) 5-methylurapidil; (b) L-765,314; or (c)
BMY 7378 in animals pretreated (i.v.) with 100 μg/kg ritanserin. Empty symbols depict either: (i) the responses to DHE in the group pretreated with
100 μg/kg ritanserin followed by 1 ml/kg saline (◇, which depicts the same data as those shown in Fig. 3, but it is illustrated here as the control for
comparative purposes); or (ii) non-significant responses (△,▽) versus control (◇). Solid symbols (▲,▼) represent significantly different responses
(P < 0.05) versus control (◇). δ P < 0.05 versus 30 μg/kg of: 5-methylurapidil (a), L-765,314 (b) or BMY 7378 (c). Data are shown as means ± SEM. Δ
Diastolic blood pressure stands for “increases in diastolic blood pressure”
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plus rauwolscine to abolish (although markedly blocked)
the DHE responses in ritanserin-pretreated rats (Fig. 4c)
cannot categorically exclude the possible role of add-
itional (although negligible) mechanisms, including an
enhanced synthesis of proconstrictor prostaglandins by
DHE, as reported by Müller-Schweinitzer [26].
The possible role of the different α1- and α2-adrenoceptor
subtypes in the responses to DHE
As suggested above, the vasopressor responses to DHE in
ritanserin-pretreated rats are mainly mediated by
rauwolscine-sensitive α2-adrenoceptors and, apparently to
a lesser extent, by prazosin-sensitive α1-adrenoceptors.
Nevertheless, these antagonists do not display selective af-
finities for distinguishing amongst their corresponding α1-
and α2-adrenoceptor subtypes (Table 1). Hence, the effects
of relatively more selective antagonists for the α1-adreno-
ceptor subtypes (i.e. 5-methylurapidil [α1A], L-765,314
[α1B] and BMY 7378 [α1D]) and the α2-adrenoceptor sub-
types (i.e. BRL44408 [α2A], imiloxan [α2B] and JP-1302
[α2C]) (Table 1) were further investigated in an attempt to
identify the subtypes involved.
The fact that the DHE responses were blocked after
administration of each of these antagonists for α1- (Fig.
5) and α2-adrenoceptors (Fig. 6) basically suggests theinvolvement of, respectively, the α1A/α1B /α1D subtypes
and the α2A/α2B/α2C subtypes. Importantly, the doses
used of these antagonists have previously been shown:
(i) to completely block the vasopressor responses medi-
ated by the α1A/α1B/α1D subtypes and the α2A/α2B/α2C
subtypes in pithed rats [10, 13]; and (ii) to correlate with
the affinities for their respective subtypes [27] (see Table
1). Notwithstanding, the differences in the profile of
blockade produced by each of the above antagonists
deserve further considerations.
On the one hand, 30–100 μg/kg of 5-methylurapidil
(Fig. 5a) and BMY 7378 (Fig. 5c) dose-dependently
blocked the DHE responses and display very high affinity
for, respectively, the α1A (pKi: 9.0) and α1D (pKi: 9.0)
subtypes, but they also display moderate affinity for the
other α1 subtypes (with pKi’s between 7.0 and 8.0; Table
1). Hence, one could imply that the high potency of
these antagonists to block the DHE responses may be
due to a marked blockade of their receptors, with partial
blockade of the other α1 subtypes. However, Zhou and
Vargas [28] showed in pithed rats that: (i) 500 μg/kg 5-
methylurapidil blocked the vasopressor responses to the
α1A-adrenoceptor agonist (R)A-61603; and (ii) 100–
1000 μg/kg BMY 7378, which dose-dependently blocked
the vasopressor responses to phenylephrine, failed to
block those to (R)A-61603. Thus, it would seem logical
Fig. 6 Increases in diastolic blood pressure by i.v. dihydroergotamine (1–3100 μg/kg) after i.v. treatment with: (a) BRL44408; (b) imiloxan; or (c) JP-1302
in animals pretreated (i.v.) with 100 μg/kg ritanserin. Empty symbols depict either: (i) the responses to DHE in the group pretreated with 100 μg/kg
ritanserin followed by 1 ml/kg saline (◇, which depicts the same data as those shown in Fig. 3, but it is illustrated here as the control for comparative
purposes); or (ii) non-significant responses (△, ▽,⎔ versus control (◇). Solid symbols (▲,▼, ) represent significantly different responses (P < 0.05)
versus control (◇). δ P < 0.05 versus 100 μg/kg BRL44408 (a), 300 μg/kg imiloxan (b) or 300 μg/kg JP-1302 (c). Data are shown as means ± SEM.
Δ Diastolic blood pressure stands for “increases in diastolic blood pressure”
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(Fig. 5c) are reasonably selective for blocking the α1A-
and α1D-subtypes, respectively, as suggested by Willems
et al. [27]. In contrast, the fact that only 100 μg/kg L-
765,314 significantly blocked the DHE responses (Fig.
5b): (i) apparently matches with its slightly lower -but
still high- affinity (pKi: 8.3) for the α1B subtype and its
moderate affinity for the α1D subtype (Table 1); and (ii)
implies a minor role of the α1B subtype (relative to that
of the α1A- and α1D- subtypes) in the systemic vascula-
ture, as suggested by Daly et al. [29].
On the other hand, as to the role of the α2-adrenocep-
tor subtypes, BRL44408 and JP-1302 are “relatively se-
lective” for, respectively, the α2A (pKi: 8.7) and α2C (pKi:
7.6) subtypes (Table 1). Thus, the high potency of
BRL44408 (100–300 μg/kg; Fig. 6a) and the lower po-
tency of JP-1302 (only at 1000 μg/kg; Fig. 6c) to block
the DHE responses might suggest a major role of the
α2A subtype and a less predominant role of the α2C sub-
type mediating vasopressor responses, as suggested by
Gavin and Docherty [30]. However, the affinities of these
antagonists for the α1- adrenoceptor subtypes have not
been determined (Table 1). Interestingly, in pithed rats
(n = 5), the vasopressor responses to i.v. bolus injections
of 0.1, 0.3, 1, 3, 10 and 30 μg/kg phenylephrine (14 ± 2,19 ± 2, 24 ± 2, 39 ± 5, 66 ± 7 and 115 ± 7 mmHg, re-
spectively): (i) remained unaltered after an i.v. bolus of
100 μg/kg BRL44408 (16 ± 2, 20 ± 2, 25 ± 3, 40 ± 6,
69 ± 9 and 107 ± 12 mmHg); and (ii) were attenuated
(at the highest doses) after an i.v. bolus of 300 μg/kg
BRL44408 (12 ± 2, 12 ± 1, 18 ± 3, 29 ± 7, *54 ± 12 and
*93 ± 16 mmHg; *P < 0.05) (unpublished observations).
The latter finding may explain why the blockade pro-
duced by BRL4408 (Fig. 6a): (i) did not significantly
differ (P > 0.05) from that produced by the combination
prazosin plus rauwolscine (Fig. 4c); and (ii) was more
pronounced than that produced by rauwolscine alone
(Fig. 4b). In contrast, the affinity of imiloxan for the α1-
adrenoceptor subtypes is very low (pKi < 4; which
excludes its interaction with these receptors), but its
affinity for the α2B (pKi: 7.3) and α2C (pKi: 6.0) subtypes
(Table 1) leaves very little room for in vivo selectivity, par-
ticularly at the doses used (Fig. 6b). Indeed, the blockade
of the DHE responses by 1000 and 3000 μg/kg imiloxan
being practically identical (Fig. 6b) seems to suggest a
minor role of the α2B (and probably also of the α2C) adre-
noceptor subtype. Hence, we considered it unnecessary to
explore the effect of more antagonist combinations.
Clearly, the above findings cannot be simply explained in
terms of pure antagonism at a single receptor subtype in
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cannot reach equilibrium conditions, nor can we categoric-
ally exclude the role of pharmacokinetic factors); (ii) the
relative “selectivity” of the antagonists used (determined
in vitro; Table 1); and (iii) the limited selectivity of these
compounds when given i.v. in pithed rats.
Potential clinical implications of the present results
Admittedly, the relative “selectivity” of the α1- and α2-
adrenoceptor antagonists used in this study (see Table 1)
would seem rather limited in view of the i.v. (systemic)
administration of compounds and the additional role of
pharmacokinetic factors (which cannot be completely
ruled out in pithed rats). Consistent with these views,
other studies performed in vivo with these compounds
have also shown limited selectivity [31]. Notwithstand-
ing, the pithed rat model is predictive of (cardio)vascular
side effects [11, 12] and provides information that can-
not be obtained from in vitro studies [32]. Moreover,
from a clinical perspective, our findings may help under-
stand the pharmacological profile of the adverse vascular
side-effects (i.e. systemic vasoconstriction) produced by
DHE (present results) and ergotamine [10], even when
the pharmacological profile of the α-adrenoceptor sub-
types mediating systemic vasoconstriction in rodents
and humans is not identical [25].
On the other hand, although the vasoconstrictor re-
sponses to DHE mediated by α1- and α2-adrenoceptors
are less pronounced (i.e. after ritanserin pretreatment;
compare Fig. 3 with Figs. 4, 5 and 6), their effects gain im-
portance in view of the long-lasting vasoconstriction in-
duced by DHE, as previously reported [23, 24]. These
findings are even more relevant from a clinical perspective
in view of the already increased cardiovascular risk in mi-
graine patients [33, 34]. Certainly, there are other drugs
for the acute treatment of migraine [2, 35, 36], including
the triptans (which produce selective cranial vasoconstric-
tion) and calcitonin gene related peptide (CGRP) receptor
antagonists and antibodies (which block the cranial vaso-
dilatation produced by trigeminal release of CGRP). Re-
garding CGRP receptor antagonists and antibodies, they
are clearly devoid of direct vasoconstrictor effects; not-
withstanding, since CGRP may play a vasodilator protect-
ive role during ischemic (cerebral and cardiac) events,
CGRP blockade could transform transient ischemic events
into lethal infarcts [36]. Thus, the pharmacological ana-
lysis of the systemic vasoconstriction induced by the clas-
sical antimigraine agent DHE is of particular relevance for
the further development of antimigraine drugs devoid of
direct, as well as indirect, vascular side effects.
Conclusion
Our results suggest that the vasopressor (systemic vaso-
constrictor) responses to DHE in ritanserin pretreatedpithed rats could be mediated by activation of α2 (prob-
ably α2A, α2B and α2C)-adrenoceptors and, apparently to
a lesser extent, by α1 (probably α1A, α1B and α1D)-adre-
noceptors. Admittedly, this conclusion is based on the
assumption that all antagonists used are relatively select-
ive (as deducted from in vitro binding data under equi-
librium conditions; Table 1) for blocking their
corresponding α-adrenoceptor (sub)types at the doses
used in the present study.
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